H W Sollinger
Overview
Explore the profile of H W Sollinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
334
Citations
2124
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arpali E, Al-Qaoud T, Martinez E, Redfield III R, Leverson G, Kaufman D, et al.
Am J Transplant
. 2018 Feb;
18(8):1977-1985.
PMID: 29446225
We aimed to evaluate the influence of urological complications occurring within the first year after kidney transplantation on long-term patient and graft outcomes, and sought to examine the impact of...
2.
Niederhaus S, Leverson G, Lorentzen D, Robillard D, Sollinger H, Pirsch J, et al.
Am J Transplant
. 2013 Oct;
13(11):2945-55.
PMID: 24102905
Antibody-mediated rejection (AMR) after pancreas transplantation is a recently identified entity. We describe the incidence of, risk factors for, and outcomes after AMR, and the correlation of C4d immunostaining and...
3.
Neidlinger N, Sollinger H
Transplant Proc
. 2010 Jul;
42(5):1402-7.
PMID: 20620444
The use of an antibody induction agent in kidney transplantation lowers the risk of an acute rejection episode and may improve graft outcomes. Antithymocyte globulin (ATG) is the most commonly...
4.
Tedesco-Silva H, Lorber M, Foster C, Sollinger H, Mendez R, Carvalho D, et al.
Clin Transplant
. 2009 Sep;
23(5):589-99.
PMID: 19719728
This exploratory, multicenter, open-label study evaluated the efficacy and safety of FTY720, as a part of an immunosuppressive regimen, in combination with everolimus and steroids in de novo renal transplant...
5.
Knechtle S, Pascual J, Bloom D, Torrealba J, Jankowska-Gan E, Burlingham W, et al.
Am J Transplant
. 2009 Apr;
9(5):1087-98.
PMID: 19344431
Alemtuzumab induction with 60 days of tacrolimus treatment and continuous sirolimus treatment prevented acute rejection in nine of 10 consecutive renal allograft recipients. All patients are alive with a functioning...
6.
Vermeulen L, Puffer E, Hallam M, Sollinger H, Hoke R, Kolesar J
Am J Transplant
. 2009 Feb;
9(3):651-2.
PMID: 19191774
No abstract available.
7.
Magliocca J, Odorico J, Pirsch J, Becker Y, Knechtle S, Leverson G, et al.
Am J Transplant
. 2008 Aug;
8(8):1702-10.
PMID: 18694474
Alemtuzumab is a humanized, rat monoclonal antibody directed against the CD52 antigen. After binding, alemtuzumab causes profound and durable depletion and has been successfully used as immune induction therapy for...
8.
Sollinger H, Becker Y, Burlingham W, DAlessandro A, Fernandez L, Hullett D, et al.
Clin Transpl
. 2008 Jul;
:271-87.
PMID: 18637475
No abstract available.
9.
Pascual J, Bloom D, Torrealba J, Brahmbhatt R, Chang Z, Sollinger H, et al.
Am J Transplant
. 2008 May;
8(7):1529-36.
PMID: 18510645
To address the results of calcineurin inhibitor (CNI) withdrawal after alemtuzumab induction relative to CNI continuation, we performed a pilot randomized clinical trial in renal allograft recipients on CNI, a...
10.
Odorico J, Voss B, Munoz del Rio A, Leverson G, Becker Y, Pirsch J, et al.
Transplant Proc
. 2008 Apr;
40(2):513-5.
PMID: 18374117
Preserving kidney function in patients after solitary pancreas transplantation (SPTx) is an important consideration, yet various factors may negatively impact long-term function of the native kidneys or kidney allograft. To...